"
Du er her: Forside > In the pit - Oslo Børs > Nordic Nanovector - det neste Algeta? (2)
Nordic Nanovector - det neste Algeta? (2)
Savepig
09.11.2016 10:40
#119

Endre
Det var en kortvarig dupp gitt. NANO må vel være en av aksjene som blir minst berørt av valget. Om noe er vel Trump til og med marginalt bedre.
Stockamateur
09.11.2016 12:56
#11270

Endre
Noen som vet hvor man kan få opp chart med volum plottet mot aksjekurs? (Vises ofte langs y-aksen i tid mot kurs plot, hvor y-aksen er kurs.) Det vanlige er å plotte både kurs og volum mot tid, da ligger volumplottet langs x-aksen (tidsaksen).

Jeg mener å huske at nerden viste slike plot (?)
highlander
09.11.2016 16:14
#6578

Endre
Kult at bruddet over 67 - eller forsøket på brudd - kommer på en dag som denne. :)
yemaya 2
09.11.2016 17:48
#7629

Endre
Kan dette gi en sammenheng:
Investing.com - Pharmaceutical stocks were boosted Wednesday by Donald Trump's surprise presidential win.
During his campaign, Trump said he would dismantle Obama's healthcare program.
Sector was sold prior to election result as Clinton was seen increasing controls on drug pricing.
In the U.S., Pfizer (NYSE:PFE) was up over 4% in pre-market trade as Mylan (NASDAQ:MYL) added over 6%.
European pharmaceuticals stocks were also higher.
Savepig
09.11.2016 23:17
#120

Endre
Jeg satt på flyet til oslo i dag og så bloomberg på norwegian sin wifi, var hardt å å være ned i 58 et sekund, men så så jeg at novo var opp 5% under en time inn i dagen, da kom hvilepulsen
bjth
10.11.2016 09:24
#25

Endre
Da fikk vi vi en positiv krysning på kurven for MACD som indikererker positiv momentum.

Dette styrker nåværende kurs, og maner vel vei for videre klatring.
bjth
11.11.2016 08:56
#28

Endre
TA viser vel en fin fortsettelse:



la5yv
11.11.2016 11:41
#2110

Endre
MLI selger ned hver gang det går opp, -av en eller annen grunn.
Men snart fosser vi videre.
bjth
14.11.2016 08:08
#30

Endre
14/11-2016 07:00:12: (NANO) Nordic Nanovector to Present at Jefferies 2016 London Healthcare Conference
Oslo, Norway, 14 November 2016

Nordic Nanovector ASA (OSE: NANO), a biotechnology company focusing on the
development and commercialisation of novel targeted therapeutics in haematology
and oncology, announces that members of its management team will participate at:

Jefferies 2016 London Healthcare Conference (16-17 November, London, UK)

Chief Executive Officer, Luigi Costa, will present an overview of the company,
including an introduction to Betalutin®, a potential first-in-class treatment
for non-Hodgkin lymphoma, its development strategy, key milestones and market
opportunities. Mr Costa will also provide a summary of the company's broader
development strategy based around building a pipeline of innovative targeted
therapies for haematological cancers.

The presentation will take place Wednesday 16 November at 08:40 GMT and the
slides presented will be made available on Nordic Nanovector's website
(www.nordicnanovector.com), Investor Relations/Reports and
Presentations/Presentations/2016.

For further information, please contact:

IR enquiries:

Luigi Costa, Chief Executive Officer
Cell: +41 79 124 8601

Tone Kvåle, Chief Financial Officer
Cell: +47 91 51 95 76
Email: ir@nordicnanovector.com

Media enquiries:
Mark Swallow/David Dible (Citigate Dewe Rogerson)
Tel: +44 207 282 2948/+44 207 282 2949
Email: nordicnanovector@citigatedr.co.uk

About Nordic Nanovector:

Nordic Nanovector is a biotech company focusing on the development and
commercialisation of novel targeted therapeutics in haematology and oncology.
The Company's lead clinical-stage product opportunity is Betalutin®, the first
in a new class of Antibody-Radionuclide-Conjugates (ARC) designed to improve
upon and complement current options for the treatment of non-Hodgkin Lymphoma
(NHL). NHL is an indication with substantial unmet medical need and orphan drug
opportunities, representing a growing market worth over $12 billion by 2018.

Betalutin® comprises a tumour-seeking anti-CD37 antibody, lilotomab (previously
referred to as HH1), conjugated to a low intensity radionuclide (lutetium-177).
The preliminary data has shown promising efficacy and safety profile in an
ongoing Phase 1/2 study in a difficult-to-treat NHL patient population. The
Company is aiming at developing Betalutin® for the treatment of major types of
NHL with first regulatory submission anticipated in 1H 2019.

Nordic Nanovector intends to retain marketing rights and to actively participate
in the commercialisation of Betalutin® in core markets, while exploring
potential distribution agreements in selected geographies. The Company is
committed to developing its ARC pipeline to treat multiple selected cancer
indications.

Further information about the Company can be found at www.nordicnanovector.com

This information is subject to the disclose requirements pursuant to section 5
-12 of the Norwegian Securities Trading Act.

Ekstern link: http://www.newsweb.no/index.jsp?messageId=413513

Nyheten er levert av OBI.

bjth
15.11.2016 08:00
#31

Endre
http://www.newsweb.no/newsweb/search.do?messageId=413625

Oslo, Norway, 15 November 2016

Nordic Nanovector ASA (OSE: NANO) is pleased to announce that Lisa Rojkjaer, MD
has joined the company today as Chief Medical Officer (CMO) and as a member of
the Executive Management Team. Dr Rojkjaer will lead all clinical development
strategy and execution and support the company's efforts to identify
opportunities to expand its pipeline of innovative targeted therapies for
haematological cancers.

Dr Rojkjaer is a board-certified haematologist with more than 15 years of global
and regional clinical development and medical affairs expertise in the biotech
and pharma industries, and has extensive experience in the development of both
biologics and small molecules in haematology and immunology. She joins Nordic
Nanovector from Novartis Pharmaceuticals where she held the position of Global
Clinical Program Head, Oncology Global Development. Her previous roles also
include CMO at Molecular Partners (Switzerland), Vice President, Head of
Clinical Development at Morphosys AG (Germany), and Head of Global Medical
Affairs, Biopharmaceuticals and Director of Clinical Development, Hematology in
the US for Novo Nordisk.

Dr Rojkjaer holds a medical degree from the University of Toronto and received
board certification in both internal medicine and hematology.

Dr Rojkjaer commented: "I am delighted to join Nordic Nanovector at this
exciting time in its development. The company's lead candidate Betalutin® is
demonstrating in clinical studies its potential to become an important new
therapy for the treatment of NHL patients. Its technology is also providing
multiple exciting new pipeline opportunities. I look forward to working with the
management team and contributing to the future growth of the company."

Luigi Costa, Chief Executive Officer, added: "I am very pleased to welcome Lisa
to the team. She brings on board strong expertise in clinical development of
novel cancer treatments, particularly in the field of haematology. Lisa's
knowledge and leadership will be key to the development of Betalutin® as well as
to support the growth of Nordic Nanovector's promising pipeline."

For further information, please contact:

For Nordic Nanovector
IR enquiries:
Luigi Costa, Chief Executive Officer
Cell: +41 79 124 8601

Tone Kvåle, Chief Financial Officer
Cell: +47 91 51 95 76
Email: ir@nordicnanovector.com

Media enquiries:
Mark Swallow/David Dible (Citigate Dewe Rogerson)
Tel: +44 207 282 2948/+44 207 282 2949
Email: nordicnanovector@citigatedr.co.uk

About Nordic Nanovector:
Nordic Nanovector is a biotech company focusing on the development and
commercialisation of novel targeted therapeutics in haematology and oncology.
The Company's lead clinical-stage product opportunity is Betalutin®, the first
in a new class of Antibody-Radionuclide-Conjugates (ARC) designed to improve
upon and complement current options for the treatment of non-Hodgkin Lymphoma
(NHL). NHL is an indication with substantial unmet medical need and orphan drug
opportunities, representing a growing market worth over $12 billion by 2018.

Betalutin® comprises a tumour-seeking anti-CD37 antibody, lilotomab (previously
referred to as HH1), conjugated to a low intensity radionuclide (lutetium-177).
The preliminary data has shown promising efficacy and safety profile in an
ongoing Phase 1/2 study in a difficult-to-treat NHL patient population. The
Company is aiming at developing Betalutin® for the treatment of major types of
NHL with first regulatory submission anticipated in 1H 2019.

Nordic Nanovector intends to retain marketing rights and to actively participate
in the commercialisation of Betalutin® in core markets, while exploring
potential distribution agreements in selected geographies. The Company is
committed to developing its ARC pipeline to treat multiple
Savepig
15.11.2016 09:27
#123

Endre
Presentasjoner fra tidligere tiltredelser. Driftig person dette:

Published on: 15/10/09

MorphoSys has appointed Dr Lisa Rojkjaer as vice president and head of clinical development.

Dr Rojkjaer joins MorphoSys from Novartis where she most recently held the position of head of medical affairs - hematology, Europe.

Before that she was global clinical programme head for Exjade, where she was responsible for all clinical activities in Europe for Novartis' haematology portfolio including Gleevec and Exjade.

Prior to Novartis, she spent five years with Novo Nordisk, in Copenhagen, Denmark, and Princeton, USA as the director of global medical affairs biopharmaceuticals and later director, clinical development haematology.

During her time with Novo Nordisk she established a global medical affairs group for biopharmaceuticals and headed the clinical development of the US haematology portfolio amongst other accomplishments.

Dr Rojkjaer is a board certified haematologist and received her medical degree from the University of Toronto, where she also did her residency in internal medicine and fellowship in haematology.

She has held academic and hospital appointments in the US, Canada and Europe.

May 31, 2012 07:10 AM Eastern Daylight Time
ZURICH-SCHLIEREN, Switzerland--(BUSINESS WIRE)--Molecular Partners AG, the leader in the discovery and development of DARPins®, a novel class of therapeutic proteins, today announced the appointment of Lisa Rojkjaer, MD as Chief Medical Officer, strengthening the existing management team.

Dr. Rojkjaer holds a medical degree from the University of Toronto and is a board-certified hematologist with over 10 years experience in drug development and commercialization in the biotech and pharma industries. She will be heading up all clinical activities at Molecular Partners by identifying and prioritizing clinical development programs of Molecular Partners in order to broaden the company's pipeline.

Commenting on the appointment, Dr. Christian Zahnd, CEO of Molecular Partners said: "We are delighted that Lisa is joining us to head up the clinical activities at Molecular Partners. She brings a wealth of knowledge and experience in the full development of biologics. With her excellent understanding of the translational and later clinical development phases and her experience on the expectations of the market, Lisa will further strengthen and complement our existing management team."

Prior to joining Molecular Partners, Dr. Rojkjaer led all proprietary clinical development programs as Vice President and Head of Clinical Development at Morphosys AG in Germany. Previously, Dr. Rojkjaer held a variety of senior positions in clinical development and medical affairs. She served as a Global Clinical Program Head in oncology development, and more recently as EU Head of Medical Affairs, Hematology at Novartis. Prior to Novartis, she spent five years with Novo Nordisk as the Head of Global Medical Affairs, Biopharmaceuticals in Denmark and later, Director of Clinical Development, Hematology in the US. In these positions, Dr. Rojkjaer was responsible for development of products and product candidates in early and late (phase I-IV) development stages.

Commenting on her appointment, Dr. Rojkjaer said: "I am very excited to be joining Molecular Partners, as only few companies have the ability to generate a pipeline of novel differentiated and very versatile compounds to truly improve patient outcomes in a variety of disease areas. I look forward to being a part of advancing these novel compounds into the clinic and beyond."
NetromO
15.11.2016 09:44
#12944

Endre

Rykter om at ABG er ute med ny analyse av NANO med target kr 90.....

Noen som har mottatt denne ?

tenfour
15.11.2016 11:14
#2882

Endre
En grei dag så langt. Nok en kompetent person har inntatt ledelsen i NANO. Begynner å smake fugl av dette....
highlander
15.11.2016 12:05
#6593

Endre
Som tidligere nevnt er retningen gitt. Bruddet opp gjennom tidligere motstand på 67 er nå bekreftet, og representerer et nytt støttenivå ved eventuelle tilbakefall fra høyere nivåer. Som bjth #28 påpeker tyder flere tekniske faktorer på videre oppgang.

Fundamentalt går det også riktig vei, så her er det bare å nyte oppturen, selv om enkelte aksjonærer vil kunne oppleve økt formuesskatt og omgjøring av stipend til studielån ved årsskiftet. :)



NetromO
15.11.2016 13:50
#12945

Endre
Jeg har problemer med å se hvor det er motstand når aksjekursen aldri har vært på disse nivåene :)

Stockamateur
15.11.2016 14:09
#11284

Endre
Bra du slenger på en smiley Netrom. Ellers hadde vi begynt å lure...

Var det forresten veldig morsomt?
NetromO
15.11.2016 14:19
#12946

Endre

Ikke VELDIG morsomt.... tenkte mer på det med et underfundig smil...

Vi gleder oss imidlertid over hver kroner kursen går oppover.

Men.... dere som er godt bevandret i såkalt teknisk analyse.... kan dere ikke spå litt om kursutviklingen.. del gjerne med oss andre dødelige.

Stockamateur
15.11.2016 14:43
#11286

Endre
OK.

Motstanden VAR altså i området 65-67. highlander opererer med 67, jeg foretrekker 65-66, men det kan absolutt diskuteres da dette ikke er absolutt vitenskap. (Det var bl.a. derfor jeg etterlyste chart med volum mot kurs istedetfor mot tid.) Disse nivåene ble besøkt 12-14/10 og 20/10, og testet grundig i forrige uke.
highlander
15.11.2016 15:22
#6596

Endre
Ja, volumveier man kan man si at tidligere motstand var i intervallet 65-67, hvilket altså representerer et sterkt støttenivå nå ved eventuelle tilbakefall fra høyere nivåer.

NetromO: Jeg skal ikke påstå at jeg er godt bevandret i teknisk analyse, men ser du på chartet til bjth #28 gir den definerte trendkanalen en god indikasjon på videre kursutvikling...

Endret 15.11.2016 15:22 av highlander
NetromO
15.11.2016 15:57
#12947

Endre

Tja, jeg har sittet godt siden 12 kroner uten å måtte kikke på noe chart... :)
Stockamateur
15.11.2016 16:23
#11289

Endre
Satt du med ned fra IPO til 12kr da?

Uten chart?
dr. Stockman
15.11.2016 16:47
#17010

Endre
Kjøpte som nevnt det jeg skulle ha til 12-13 kr, og har siden verken kjøpt eller solgt. Kan imidlertid komme til å ta litt gevinst på 500 kr (muligens 1/3 av aksjene) - forutsatt at potensialet på det tidspunktet ikke har skutt enda mer til himmels. Men den kursen oppnås neppe før 2018.
dr. Stockman
15.11.2016 16:47
#17011

Endre
.

Endret 15.11.2016 16:47 av dr. Stockman
renud
15.11.2016 16:59
#14247

Endre
Det er bare å legge seg flat for dere som er med på denne fantastiske kursutviklingen.
Selv bommet jeg på en inngang da kursen var under 15 kroner, ventet så på en korreksjon tilbake på 25-30-tallet, og hadde da mange muligheter som jeg ikke benyttet, og har siden syntes at aksjen var alt for dyr.

Skal si fra når jeg får ut finger'n og endelig kjøper, da er det nemlig garantert fornuftig for dere andre å dumpe...
Savepig
15.11.2016 17:46
#124

Endre
Kan du ikke heller kjøpe på duppen på 69 nå straks da? Kursen har jo tatt en tur ned etter hver eneste topp av denne typen.

Om Q3 rapporten og nye data på Ash er lovende så kan den fint finne på å gå videre fra 80 innen veldig kort tid.



Stocktalk.no eies av MarketMind AS
Adresse: Thunesvei 2, 0274 Oslo Tlf: 21 07 50 08 Email: st [at] stocktalk.no Orgnr: 979 175 027 MVA
Kontakt oss | Hjelp | Regler | Sett som startside | Legg til favoritter © 2008 Vestover AS